Answers are grounded in this paper and cite their sources.
Investigates the effects of the adrenergic blocking agent Dibenamine on severe hypertension, suggesting a therapeutic role for sympatholytic drugs.
Article1 September 1950THE EFFECTS OF DIBENAMINE ON SEVERE HYPERTENSIONRICHARD E. WUNSCH, M.D., ROBERT D. WARNKE, M.D., GORDON B. MYERS, M.D., F.A.C.P.RICHARD E. WUNSCH, M.D., ROBERT D. WARNKE, M.D., GORDON B. MYERS, M.D., F.A.C.P.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-33-3-613 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe well known rôle of the sympathetic nervous system in hypertension has led to search for sympatholytic drugs for therapeutic purposes. An extensive study of the sympatholytic agent, N-N-dibenzyl-β-chlorethylamine (Dibenamine†) in experimental animals has revealed the following pharmacological effects:1, 2, 3, 4, 5, 6, 7, 8(1) blockade of the usual pressor response to epinephrine and replacement by a depressor response; (2) prevention of ventricular tachycardia and fibrillation, ordinarily produced by toxic doses of epinephrine in dogs; (3) production of miosis and extension of the nictitating membrane in cats; (4) reduction of experimentally induced renal hypertension in rats and dogs;...Bibliography1. NickersonGoodman MLS: The pharmacology of a series of new sympatholytic agents, Am. Fed. Clin. Res. 2: 109-110, 1945. MedlineGoogle Scholar2. NickersonGoodman MLS: Pharmacological properties of a new adrenergic blocking agent (Dibenamine), J. Pharmacol. and Exper. Therap. 89: 167-185, 1947. MedlineGoogle Scholar3. NickersonNomaguchi MG: Relation of structure to activity in a new series of sympatholytic agents, Federation Proc. 5: 195, 1946. Google Scholar4. NickersonSmithGoodman MSMLS: The prevention of epinephrinecyclopropane irregularities in dogs with dibenzyl-β-chlorethylamine, Federation Proc. 5: 195, 1946. Google Scholar5. RaabHumphreys WJ: Drug action upon myocardial epinephrine-sympathin concentration and heart rate, J. Pharmacol. and Exper. Therap. 89: 64-76, 1947. MedlineGoogle Scholar6. Haimovici H: Inhibitory effect of Dibenamine on vasoconstrictor substances, Proc. Soc. Exper. Biol. and Med. 64: 486-488, 1947. CrossrefMedlineGoogle Scholar7. WilburneKatzRodbardSurtskin MLNSA: The action of N-N-dibenzyl-beta-chlorethylamine (Dibenamine) in hypertensive dogs, J. Pharmacol. and Exper. Therap. 90: 215-223, 1947. MedlineGoogle Scholar8. MaddockRankinYoumans WOUMWB: Prevention of the anti-curare action of epinephrine by Dibenamine, Proc. Soc. Exper. Biol. and Med. 67: 151-154, 1948. CrossrefMedlineGoogle Scholar9. NickersonNomaguchi MG: Locus of the adrenergic blocking action of Dibenamine, J. Pharmacol. and Exper. Therap. 93: 40-51, 1948. MedlineGoogle Scholar10. De Vleeschhouwer GR: Pharmacology of dibenzyl-β-chlorethylamine hydrochloride (Dibenamine), Proc. Soc. Exper. Biol. and Med. 66: 151-152, 1947. CrossrefMedlineGoogle Scholar11. YoumansRankin WBUM: Effects of Dibenamine on cardiovascular actions of epinephrine, acetylcholine, pitressin and angiotonin in unanesthetized dogs, Proc. Soc. Exper. Biol. and Med. 66: 241-244, 1947. CrossrefMedlineGoogle Scholar12. HechtAnderson HHRB: The influence of Dibenamine on certain functions of the sympathetic nervous system in man, Am. J. Med. 3: 1-17, 1947. CrossrefGoogle Scholar13. HaimoviciMedinets HHE: Effect of Dibenamine on blood pressure in normotensive and hypertensive subjects, Proc. Soc. Exper. Biol. and Med. 67: 163-166, 1948. CrossrefMedlineGoogle Scholar14. AchesonMoe GHGK: Action of tetraethylammonium ion on mammalian circulation, J. Pharmacol. and Exper. Therap. 87: 220-236, 1946. MedlineGoogle Scholar15. Rockwell FV: To be published in Psychosom. Med. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Detroit, Michigan*Received for publication September 30, 1948.From the Department of Medicine of Wayne University College of Medicine and the City of Detroit Receiving Hospital, Detroit, Michigan.†Trade mark of Givauden-Delawanna, Inc., New York, N. Y. Supplied through the courtesy of Dr. W. S. Gump. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byADRENERGIC BLOCKING DRUGS4 2-HalogenoalkylaminesBehandlung der benignen und malignen HypertonieHypertonieHypertonieAdrenal tumorsPHEOCHROMOCYTOMA: THE VALUE OF CERTAIN TESTS USED ROUTINELY IN DIAGNOSIS*EDWARD S. ORGAIN, M.D., F.A.C.P.Die Keimdrüsen und ihre KrankheitenExperiences with Perorally Induced «Adrenergic Block«EXPERIMENTAL HYPERTENSION*D. M. GREEN, M.D., F.A.C.P.CLINICAL EXPERIENCE WITH SYMPATHETIC BLOCKING AGENTS IN PERIPHERAL VASCULAR DISEASE*MARVIN MOSER, ANDREW G. PRANDONI, M.D., JAMES A. ORBISON, THOMAS W. MATTINGLYThe Medical Management of Arterial HypertensionTHE MANAGEMENT OF MALIGNANT HYPERTENSION*MAURICE SOKOLOW, M.D., F.A.C.P., MARY F. SCHOTTSTAEDT, M.D.The natural history and course of hypertension with papilledema (Malignant Hypertension)Treatment of essential hypertension with β-alkylamines, especially dibenzylineThe Action of SKF 688A (Phenoxyethyl Derivative of Dibenamine) upon Certain Functions of the Sympathetic Nervous System in ManClinical Applications of Adrenergic Blockade in Vascular Diseases With Special Reference To Dibenamine and 688aRe-evaluation of the reliability of pharmacologic and cold pressor studies in hypertension and pheochromocytomaFalse-Positive Test for Pheochromocytoma with an Adrenolytic Compound 1 September 1950Volume 33, Issue 3Page: 613-628KeywordsAtrial fibrillationDrug therapyDrugsEpinephrineHospital medicineHypertensionSympathetic nervous systemVentricular tachycardia Issue Published: 1 September 1950 PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Wunsch et al. (1950) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: